Description

Cancer cell dormancy plays a pivotal role in relapse and drug resistance. In the past year, we identified AXL as a potential key regulator of myeloma cell dormancy. AXL is a receptor tyrosine kinase that can drive wide- ranging processes ranging from angiogenesis, dormancy and resistance to therapy. In this project we wish to investigate whether in-house made GAS6/AXL blocking nanobodies are able to reactivate dormant myeloma cells, hence making them more susceptible to chemotherapy. The process will be visualized using intravital imaging. Chemotherapy-induced AXL expression will be evaluated and combination therapy conducted to validate AXL as a potential therapeutic target.
AcronymAIIFUND53
StatusActive
Effective start/end date10/01/2031/12/21

    Research areas

  • MULTIPLE MYELOMA, Therapy

    Flemish discipline codes

  • Cancer therapy
  • Cancer biology

ID: 48955491